Development and validation of a quantitative Orthopoxvirus immunoassay to evaluate and differentiate serological responses to Mpox infection and vaccination
Authors:
Open Access
- 22 February 2025
- journal article
- Published by Elsevier in EBioMedicine
- Vol. 113, 105622
Abstract
No abstract availableKeywords
Funding Information
- University College Dublin
- Health Research Board
This publication has 25 references indexed in Scilit:
- Shifting transmission patterns of human mpox in South Kivu, DR CongoThe Lancet Infectious Diseases, 2024
- Underdetected dispersal and extensive local transmission drove the 2022 mpox epidemicCell, 2024
- Human antibody responses to circulating monkeypox virus emphasise the need for the first mpox-specific vaccineThe Lancet Microbe, 2024
- Mpox neutralising antibodies at 6 months from mpox infection or MVA-BN vaccination: a comparative analysisThe Lancet Infectious Diseases, 2023
- Mpox in people with past infection or a complete vaccination course: a global case seriesThe Lancet Infectious Diseases, 2023
- Mpox vaccine and infection-driven human immune signatures: an immunological analysis of an observational studyThe Lancet Infectious Diseases, 2023
- The global landscape of smallpox vaccination history and implications for current and future orthopoxvirus susceptibility: a modelling studyThe Lancet Infectious Diseases, 2022
- Sex difference in immune response to vaccination: A participant-level meta-analysis of randomized trials of IMVAMUNE ® smallpox vaccineVaccine, 2015
- Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulinVirology, 2004
- The Complete Genomic Sequence of the Modified Vaccinia Ankara Strain: Comparison with Other OrthopoxvirusesVirology, 1998